The Latest Cardiac and Vascular News
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH). The global license […]
CLEVELAND, Jan. 24, 2019 /PRNewswire/ — Centerline Biomedical, Inc., announced on January 22nd that the company submitted a 510(k) premarket notification application to the United States Food and Drug Administration (FDA) for its flagship product, the Intra-Operative Positioning System, IOPS. IOPS, a non-radiation-based surgical navigation system for minimally invasive surgery, leverages anatomical mapping and modeling […]
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol […]
HINGHAM, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with institutional investors for the purchase of 250,000 shares of its common stock, […]
EDEN PRAIRIE, Minn., Jan. 24, 2019 (GLOBE NEWSWIRE) — In a release issued this morning by CHF Solutions, we have been advised by the company that the headline should read “Cardiothoracic Surgeon Daniel Beckles” rather than “Cardiologist Daniel Beckles” as originally issued. The corrected release follows: CHF Solutions (Nasdaq: CHFS), today announced […]
TEL AVIV, Israel, Jan. 24, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the presentation of positive interim results from an investigator-initiated study of CGuard™ EPS. […]
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Lee’s Pharmaceutical Holdings Limited and its subsidiaries (collectively “Lee’s Pharmaceutical”) has completed its Phase […]
ST. LOUIS, Jan. 24, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to arrhythmia patients. Kansas City Heart Rhythm Institute (KCHRI), a […]
ATLANTA, Jan. 24, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA approval of an early feasibility study IDE to evaluate the safety and feasibility of the Cor™ TRICUSPID ECM® cardiac valve for adults with endocarditis and for pediatric patients with congenital heart valve disease. The […]
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–The GORE® TIGRIS® Vascular Stent, a flexible self-expanding stent to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) developed by W. L. Gore & Associates, Inc. (Gore), demonstrated that it is a safe and effective device that can be incorporated […]
